However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company says could lead to faster and more complete disease control.

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...

The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve ...

The British pharma is adding $500 million, and ADC production capabilities, to a planned Virginia facility. Elsewhere, ...

The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically ...

Nilo Therapeutics, which launched Wednesday, is trying to develop drugs that regulate inflammation and the immune system by ...

The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but some analysts see it ...

The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other therapies for ...

Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the ...

Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work ...

The agency will consider a submission that includes pooled data from ongoing studies, a decision analysts viewed as a notable ...